NDAIONTOPHORESISSYSTEM
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Data completeness
4/8 — Partial
ZECUITY (sumatriptan succinate) by Teva is 5-ht 1b/1d receptors. First approved in 2013.
Drug data last refreshed 5h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZECUITY is a transdermal iontophoretic system delivering sumatriptan succinate for acute migraine treatment. It works by agonizing 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vasoconstriction and inhibiting pro-inflammatory neuropeptide release. This innovative delivery method offers an alternative to oral and injectable migraine therapies.
Peak6.0 years to LOE
Product at peak lifecycle stage with stable market position; commercial team likely focused on market maintenance and managed care optimization.
Mechanism of Action
5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine
Started Aug 2013
37 enrolled
Acute Migraine
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
Started May 2008
30 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Started Dec 2006
169 enrolled
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Started Nov 2006
173 enrolled
Migraine Disorders
Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan
Started Jun 2006
75 enrolled
Migraine Disorders
Worked on ZECUITY at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.